A phase 3 multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aducanumab (BIIB037) in subjects with early Alzheimer's Disease (2015–2022)

Grant type:
Biogen Australia
  • Professor
    Royal Brisbane Clinical Unit
    Faculty of Medicine
    Affiliate Professor
    UQ Centre for Clinical Research
    Faculty of Medicine
Funded by:
Biogen Australia Pty Ltd